1
|
Cui P, Tang Z, Zhan Q, Deng C, Lai Y, Zhu F, Xin H, Li R, Chen A, Tong Y. In vitro and vivo study of tranilast protects from acute respiratory distress syndrome and early pulmonary fibrosis induced by smoke inhalation. Burns 2022; 48:880-895. [PMID: 35410697 DOI: 10.1016/j.burns.2022.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/14/2022] [Accepted: 03/15/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Tranilast (N-[3',4'-dimethoxycinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite. It was identified with anti-inflammatory and antifibrotic activities, and used in the treatment of a variety of diseases, such as anti - allergy, bronchial asthma, and hypertrophic scars. As a drug with few adverse reactions, tranilast has attracted great attention, but its application is limited due to the uncertainty of dosages and mechanisms. In this study, the protection effects of different doses of tranilast on smoke inhalation mediated lung injury on rats, and on the damage of three kinds of lung cells in vitro were investigated. METHOD In vivo, Sprague-Dawley rats were randomly divided into sham group, smoke group (rats were exposed to pine sawdust smoke three times, each time for 5 min), different doses of tranilast treatment group (doses were 100 mg/kg, 200 mg/kg and 300 mg/kg, ip.) and placebo group. After 1, 3 and 7 days, pulmonary function, pathologic injury by HE staining, cytokines and oxidative stress level by kits were determined. At 7days, lung fibrosis was assessed by Masson's trichrome staining and the level of hydroxyproline (HYP). In vitro, three kinds of lung cells from normal rats were isolated: type II alveolar epithelial cells (AT-II), pulmonary microvascular endothelial cells (PMVECs) and pulmonary fibroblasts (PFs). To investigate the potential effects of tranilast on cell proliferation, cell cycle and cytokine production of three kinds of lung cells exposed to smoke. RESULTS Compared with smoke group and placebo group, tranilast treatment significantly reduced histopathological changes (such as pulmonary hemorrhage, edema and inflammatory cell infiltration, etc.), significantly reduced histopathological score (p < 0.05), increased arterial oxygen partial pressure, and decreased the levels of IL-1β, TNF-α, TGF-β1 (p < 0.05), oxidative stress and the expression of nuclear transcription factor κB (NF-κB) smoke exposed rats (p < 0.01). In particular, the effect of 200 mg/kg dose was more prominent. In vitro, smoke induced AT-II and PMVECs apoptosis, improved PFs proliferation (p < 0.01), activity of SOD and decreased the content of MDA (p < 0.01). However, tranilast seems to be turning this trend well. The inflammatory factor IL-11β, TNF-α and TGF-β1, and the expression of NF-κB were significantly lower in the tranilast treatment than in the smoke group (p < 0.01). CONCLUSION This study indicates that tranilast had a protective effect on acute respiratory distress syndrome and early pulmonary fibrosis of rats in vivo. In addition, tranilast promotes proliferation of AT-II and PMVECs but inhibits PFs proliferation, down-regulates secretion of inflammatory cytokines and alleviates oxidative stress of AT-II, PMVECs and PFs after smoke stimuli in vitro.
Collapse
Affiliation(s)
- Pei Cui
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Zhiping Tang
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Qiu Zhan
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Chunjiang Deng
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Yanhua Lai
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Fujun Zhu
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Haiming Xin
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Rongsheng Li
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Anning Chen
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China
| | - Yalin Tong
- Department of Burns, Plastic and Wound Repair Surgery, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China; Animal Laboratory, The 924th Hospital of the Joint Logistics Support Force of Chinese PLA, Guilin 541002, China.
| |
Collapse
|
2
|
Kong M, Lee J, Yazdi IK, Miri AK, Lin YD, Seo J, Zhang YS, Khademhosseini A, Shin SR. Cardiac Fibrotic Remodeling on a Chip with Dynamic Mechanical Stimulation. Adv Healthc Mater 2019; 8:e1801146. [PMID: 30609312 PMCID: PMC6546425 DOI: 10.1002/adhm.201801146] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 11/07/2018] [Indexed: 12/19/2022]
Abstract
Cardiac tissue is characterized by being dynamic and contractile, imparting the important role of biomechanical cues in the regulation of normal physiological activity or pathological remodeling. However, the dynamic mechanical tension ability also varies due to extracellular matrix remodeling in fibrosis, accompanied with the phenotypic transition from cardiac fibroblasts (CFs) to myofibroblasts. It is hypothesized that the dynamic mechanical tension ability regulates cardiac phenotypic transition within fibrosis in a strain-mediated manner. In this study, a microdevice that is able to simultaneously and accurately mimic the biomechanical properties of the cardiac physiological and pathological microenvironment is developed. The microdevice can apply cyclic compressions with gradient magnitudes (5-20%) and tunable frequency onto gelatin methacryloyl (GelMA) hydrogels laden with CFs, and also enables the integration of cytokines. The strain-response correlations between mechanical compression and CFs spreading, and proliferation and fibrotic phenotype remolding, are investigated. Results reveal that mechanical compression plays a crucial role in the CFs phenotypic transition, depending on the strain of mechanical load and myofibroblast maturity of CFs encapsulated in GelMA hydrogels. The results provide evidence regarding the strain-response correlation of mechanical stimulation in CFs phenotypic remodeling, which can be used to develop new preventive or therapeutic strategies for cardiac fibrosis.
Collapse
Affiliation(s)
- Ming Kong
- College of Marine Life Science, Ocean University of China, Yushan Road, Qingdao, Shandong Province 266003, China
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Junmin Lee
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
- Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA90095, USA
- Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA90095, USA
- California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA90095, USA
| | - Iman K. Yazdi
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
| | - Amir K. Miri
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Yi-Dong Lin
- Divisions of Genetics and Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA02115, USA
| | - Jungmok Seo
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Center for Biomaterials, Biomedical Research Institute, Korea Institute of Science and Technology, 14 Hwarang-ro, Seongbuk-gu, Seoul, 02792, Republic of Korea
| | - Yu Shrike Zhang
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ali Khademhosseini
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA90095, USA
- Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA90095, USA
- Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA90095, USA
- California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA90095, USA
- Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul 05029, Republic of Korea
| | - Su Ryon Shin
- Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| |
Collapse
|